LEWISVILLE, Texas--(BUSINESS WIRE)--
Orthofix International N.V. (NASDAQ:OFIX), a diversified, global medical
device company, today announced that it will participate in the
Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 in New
York City. President and Chief Executive Officer Brad Mason will
represent the Company in a presentation scheduled for 10:30 a.m. ET.
A live audio webcast will be available on the Company's website at www.orthofix.com
by clicking on the Investors tab and then clicking the link on the
Events and Presentations page.
About Orthofix
Orthofix International N.V. is a diversified, global medical device
company focused on improving patients' lives by providing superior
reconstructive and regenerative orthopedic and spine solutions to
physicians worldwide. Headquartered in Lewisville, Texas, the Company
has four strategic business units that include BioStim, Biologics,
Extremity Fixation and Spine Fixation. Orthofix products are widely
distributed via the Company's sales representatives, distributors and
its subsidiaries. In addition, Orthofix is collaborating on research and
development activities with leading clinical organizations such as the
Musculoskeletal Transplant Foundation and the Texas Scottish Rite
Hospital for Children. For more information, please visit www.orthofix.com.
Forward-Looking Statements
Mr. Mason's presentation on June 9, 2016 at the Jefferies 2016
Healthcare Conference is expected to contain certain forward-looking
statements under the Private Securities Litigation Reform Act of 1995.
The forward-looking statements, which may include, but are not limited
to, statements concerning the projections, financial condition, results
of operations and businesses of Orthofix and its subsidiaries, will be
based on management's expectations and estimates at such time, and may
involve risks and uncertainties that could cause actual results or
outcomes to differ materially from those contemplated by the
forward-looking statements.
Any forward-looking statements in Mr. Mason's presentation will not
constitute guarantees or promises of future performance. Factors that
could cause or contribute to such differences may include, but are not
limited to, risks relating to: the expected sales of our products,
including recently launched products; the continuation of our ongoing
share repurchase program; an investigation by the Division of
Enforcement of the Securities and Exchange Commission (the "SEC") and
related securities class action litigation arising out of our prior
accounting review and restatements of financial statements; our review
of allegations of improper payments involving our Brazil-based
subsidiary; the geographic concentration of certain of our sales and
accounts receivable in countries or territories that are facing severe
fiscal challenges; unanticipated expenditures; changing relationships
with customers, suppliers, strategic partners and lenders; changes to
and the interpretation of governmental regulations; the resolution of
pending litigation matters (including our indemnification obligations
with respect to certain product liability claims against our former
sports medicine global business unit); our ongoing compliance
obligations under a corporate integrity agreement with the Office of
Inspector General of the Department of Health and Human Services (and
related terms of probation) and a deferred prosecution agreement with
the U.S. Department of Justice; risks relating to the protection of
intellectual property; changes to the reimbursement policies of third
parties; the impact of competitive products; changes to the competitive
environment; the acceptance of new products in the market; conditions of
the orthopedic and spine industry; credit markets and the global
economy; corporate development and market development activities,
including acquisitions or divestitures; unexpected costs or operating
unit performance related to recent acquisitions; and other risks
described in the "Risk Factors" section of our Annual Report on Form
10-K for the fiscal year ended December 31, 2015, as well as in other
reports that we file in the future. Existing and prospective investors
are cautioned not to place undue reliance on these forward-looking
statements, which will speak only as of the date of the presentation.
The Company will undertake no obligation to update or revise the
information contained in the presentation.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160526006483/en/
Orthofix International N.V
Investor Relations
Mark
Quick, 214-937-2924
markquick@orthofix.com
or
Media
Relations
Denise Landry, 214-937-2529
deniselandry@orthofix.com
Source: Orthofix International N.V
News Provided by Acquire Media